<DOC>
	<DOCNO>NCT00435227</DOCNO>
	<brief_summary>- The purpose study describe effect single ( IM ) dose motavizumab upper respiratory tract child present RSV illness require hospitalization time presentation - Describe effect single 30 mg/kg IM dose motavizumab decrease need hospitalization due worsen RSV illness child receive outpatient treatment - Describe effect single 30 mg/kg IM dose motavizumab subsequent respiratory status measure Respiratory Assessment Change Score ( RACS ) change oxygen saturation - For child require hospitalization , describe effect motavizumab severity RSV illness hospitalization [ i.e. , RACS , oxygen saturation , heart rate , use supplemental oxygen , mechanical ventilation , duration intensive care unit ( ICU ) stay ] - Describe effect single 30 mg/kg IM dose motavizumab duration symptom RSV illness ( fever , coryza , cough , parental opinion return normal health activity ) - Describe nasal concentration motavizumab follow single 30mg/kg dose - Describe serum pharmacokinetics immunogenicity single 30 mg/kg IM dose motavizumab - Describe effect motavizumab marker inflammation measure gene microarray cytokine level - Evaluate safety tolerability single 30 mg/kg IM dose motavizumab outpatient treatment child RSV - Describe progression severity lower respiratory infection ( LRI )</brief_summary>
	<brief_title>A Study Evaluate Single IM Dose Motavizumab Treatment Children With RSV ( Respiratory Syncytial Virus ) Illness</brief_title>
	<detailed_description>This Phase 2 , randomize , double-blind , placebo-controlled , multicenter study determine effect single 30 mg/kg IM dose motavizumab viral load motavizumab level upper respiratory tract child present RSV illness require hospitalization . Using 1:1 randomization , 30 mg/kg motavizumab placebo administer soon possible child 's diagnosis RSV his/her eligibility study confirm .</detailed_description>
	<criteria>Previously healthy Age ≤12 month time randomization Weight ≤10 kg time randomization Gestational age ≥36 week RSV illness ( must coryza ) document positive RSV test time evaluation Documented stable clinical condition require hospitalization ( oxygen saturation ≥ 95 % ; respiratory rate &lt; 60 breaths/min child &lt; 2 month &lt; 50 breaths/min child 212 month ) Respiratory Distress Assessment Instrument ( RDAI ) score ≤ 6 ( 1 point assign 6 assessment category ) baseline evaluation Randomization within 4 hour evaluate positive Binax® RSV test Written inform consent obtain patient 's parent ( ) legal guardian Prior receipt receive treatment steroid ( except topical steroid ) prior randomization Prior medically diagnose RSV infection Prior receipt receive antiviral treatment current episode RSV infection prior randomization Any medically significant underlie ongoing chronic illness organ system dysfunction know acute illness , acute RSV infection Known renal impairment , hepatic dysfunction , hematologic abnormality , seizure neurologic disorder immunodeficiency Requirement supplemental oxygen ( brief use oxygen immediate postnatal period treat transient condition allow ) Mechanical ventilation time prior onset current RSV infection Congenital heart disease [ child medically surgically closed patent ductus arteriosus ( PDA ) , small atrial septal defect ( ASD ) small ventricular septal defect ( VSD ) allow ] Previous reaction intravenous immunoglobulin ( IVIG ) , blood product , foreign protein Prior use IVIG , RSVIGIV ( RespiGam® ) , motavizumab immunoglobulin product within past 2 month Prior use palivizumab ( Synagis® ) within past 2 month Currently receive investigational agent receive investigational agent within last 3 month Prior current participation investigational study therapeutic agent vaccine RSV</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Respiratory Syncytial Viruses</keyword>
</DOC>